摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4-Morpholinopyrrolidin-3-ol | 524070-33-5

中文名称
——
中文别名
——
英文名称
4-Morpholinopyrrolidin-3-ol
英文别名
4-morpholin-4-ylpyrrolidin-3-ol
4-Morpholinopyrrolidin-3-ol化学式
CAS
524070-33-5
化学式
C8H16N2O2
mdl
——
分子量
172.22
InChiKey
XTYNAFYREQNMKG-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    -1.3
  • 重原子数:
    12
  • 可旋转键数:
    1
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    1.0
  • 拓扑面积:
    44.7
  • 氢给体数:
    2
  • 氢受体数:
    4

文献信息

  • FLAP MODULATORS
    申请人:JANSSEN PHARMACEUTICA NV
    公开号:US20150259357A1
    公开(公告)日:2015-09-17
    The present invention relates to compounds of Formula (I), or a form thereof, wherein ring A, R 1 , R 2 , R 3 , R 3 ′, L, W, and V are as defined herein, useful as FLAP modulators. The invention also relates to pharmaceutical compositions comprising compounds of Formula (I). Methods of making and using the compounds of Formula (I) are also within the scope of the invention
    本发明涉及式(I)的化合物,或其形式,其中环A,R1,R2,R3,R3',L,W和V如本文所定义,可用作FLAP调节剂。该发明还涉及包含式(I)化合物的药物组合物。制备和使用式(I)化合物的方法也属于本发明的范围。
  • [EN] NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS<br/>[FR] NOUVEAUX COMPOSÉS ET COMPOSITIONS PHARMACEUTIQUES LES COMPRENANT POUR LE TRAITEMENT DE TROUBLES INFLAMMATOIRES
    申请人:GALAPAGOS NV
    公开号:WO2014202458A1
    公开(公告)日:2014-12-24
    The present invention discloses compounds according to Formula I: Wherein R 1a, R 1b, R 2, R 4, R5, R 6, R 7, R 8, W, X, Y, Z, Cy, and the subscript a are as defined herein. The present invention relates to compounds inhibiting autotaxin (NPP2 or ENPP2), methods for their production, pharmaceutical compositions comprising the same, and methods of treatment using the same, for the prophylaxis and/or treatment of diseases involving fibrotic diseases,proliferative diseases, inflammatory diseases, autoimmune diseases, respiratory diseases, cardiovascular diseases, neurodegenerative diseases, dermatological disorders, and/or abnormal angiogenesis associated diseases by administering the compound of the invention.
    本发明公开了根据式I的化合物:其中R 1a、R 1b、R 2、R 4、R5、R 6、R 7、R 8、W、X、Y、Z、Cy和下标a如本文所定义。本发明涉及抑制自体脂肪酶(NPP2或ENPP2)的化合物,其制备方法,包含其的药物组合物,以及使用该化合物进行预防和/或治疗涉及纤维化疾病、增殖性疾病、炎症性疾病、自身免疫疾病、呼吸系统疾病、心血管疾病、神经退行性疾病、皮肤病和/或与异常血管生成相关疾病的方法。
  • SUBSTITUTED AMINOTHIAZOLONE INDAZOLES AS ESTROGEN RELATED RECEPTOR-ALPHA MODULATORS
    申请人:BIGNAN Gilles
    公开号:US20110150864A1
    公开(公告)日:2011-06-23
    The present invention relates to compounds of Formula (I), methods for preparing these compounds, compositions, intermediates and derivatives thereof and for treating a condition including but not limited to ankylosing spondylitis, artherosclerosis, arthritis (such as rheumatoid arthritis, infectious arthritis, childhood arthritis, psoriatic arthritis, reactive arthritis), bone-related diseases (including those related to bone formation), breast cancer (including those unresponsive to anti-estrogen therapy), cardiovascular disorders, cartilage-related disease (such as cartilage injury/loss, cartilage degeneration, and those related to cartilage formation), chondrodysplasia, chondrosarcoma, chronic back injury, chronic bronchitis, chronic inflammatory airway disease, chronic obstructive pulmonary disease, diabetes, disorders of energy homeostasis, gout, pseudogout, lipid disorders, metabolic syndrome, multiple myeloma, obesity, osteoarthritis, osteogenesis imperfecta, osteolytic bone metastasis, osteomalacia, osteoporosis, Paget's disease, periodontal disease, polymyalgia rheumatica, Reiter's syndrome, repetitive stress injury, hyperglycemia, elevated blood glucose level, and insulin resistance.
    该发明涉及式(I)的化合物,制备这些化合物的方法,组合物,中间体及其衍生物,并用于治疗包括但不限于强直性脊柱炎、动脉粥样硬化、关节炎(如类风湿性关节炎、感染性关节炎、儿童关节炎、银屑病性关节炎、反应性关节炎)、与骨相关的疾病(包括与骨形成有关的疾病)、乳腺癌(包括对抗雌激素治疗无效的癌症)、心血管疾病、软骨相关疾病(如软骨损伤/丧失、软骨退化以及与软骨形成有关的疾病)、软骨发育不良、软骨肉瘤、慢性腰部损伤、慢性支气管炎、慢性炎症性气道疾病、慢性阻塞性肺疾病、糖尿病、能量稳态紊乱、痛风、假性痛风、脂质紊乱、代谢综合征、多发性骨髓瘤、肥胖、骨关节炎、遗传性骨发育不全、骨转移性溶骨性转移、软骨软化症、骨质疏松症、帕金森病、牙周病、多肌痛风、Reiter综合征、重复性应激损伤、高血糖、血糖水平升高和胰岛素抵抗等疾病的条件。
  • NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS
    申请人:GALAPAGOS NV
    公开号:US20160214986A1
    公开(公告)日:2016-07-28
    The present invention discloses compounds according to Formula I: Wherein R 1a , R 1b , R 2 , R 4 , R 5 , R 6 , R 7 , R 8 , W, X, Y, Z, Cy, and the subscript a are as defined herein. The present invention relates to compounds inhibiting autotaxin (NPP2 or ENPP2), methods for their production, pharmaceutical compositions comprising the same, and methods of treatment using the same, for the prophylaxis and/or treatment of diseases involving fibrotic diseases, proliferative diseases, inflammatory diseases, autoimmune diseases, respiratory diseases, cardiovascular diseases, neurodegenerative diseases, dermatological disorders, and/or abnormal angiogenesis associated diseases by administering the compound of the invention.
    本发明揭示了公式I所示的化合物:其中R1a、R1b、R2、R4、R5、R6、R7、R8、W、X、Y、Z、Cy和下标a的定义如本文所述。本发明涉及抑制自体脂肪酸酰化酶(NPP2或ENPP2)的化合物,其制备方法,包含这些化合物的制药组合物,以及使用本发明中的化合物进行预防和/或治疗涉及纤维化疾病、增生性疾病、炎症性疾病、自身免疫性疾病、呼吸系统疾病、心血管疾病、神经退行性疾病、皮肤疾病和/或异常血管生成相关疾病的方法。
  • US8263781B2
    申请人:——
    公开号:US8263781B2
    公开(公告)日:2012-09-11
查看更多

同类化合物

(4-甲基环戊-1-烯-1-基)(吗啉-4-基)甲酮 (2-肟基-氰基乙酸乙酯)-N,N-二甲基-吗啉基脲六氟磷酸酯 鲸蜡基乙基吗啉氮鎓乙基硫酸盐 马啉乙磺酸钾 预分散OTOS-80 顺式4-(氮杂环丁烷-3-基)-2,2-二甲基吗啉 顺式-N-亚硝基-2,6-二甲基吗啉 顺式-3,5-二甲基吗啉 顺-2,6-二甲基-4-(4-硝基苯基)吗啉 非屈酯 雷奈佐利二聚体 阿瑞杂质9 阿瑞吡坦磷的二卞酯 阿瑞吡坦杂质 阿瑞吡坦杂质 阿瑞吡坦 阿瑞吡坦 阿瑞匹坦非对映异构体2R3R1R 阿瑞匹坦杂质A异构体 阿瑞匹坦杂质54 阿瑞匹坦-M3代谢物 钾[2 - (吗啉- 4 -基)乙氧基]甲基三氟硼酸 邻苯二甲酸单吗啉 调节安 试剂2-(4-Morpholino)ethyl2-bromoisobutyrate 茂硫磷 苯甲腈,2-(4-吗啉基)-5-[1,4,5,6-四氢-4-(羟甲基)-6-羰基-3-哒嗪基]- 苯甲曲秦 苯甲吗啉酮 苯基2-(2-苯基吗啉-4-基)乙基碳酸酯盐酸盐 苯二甲吗啉一氢酒石酸盐 苯二甲吗啉 苯乙酮 O-(吗啉基羰基甲基)肟 芬美曲秦 芬布酯盐酸盐 芬布酯 脾脏酪氨酸激酶(SYK)抑制剂 脱氯利伐沙班 脱氟雷奈佐利 羟基1-(3-氯苯基)-2-[(1,1-二甲基乙基)氨基]-1-丙酮盐酸盐 福沙匹坦苄酯 福沙匹坦杂质26 福曲他明 碘化N-甲基丙基吗啉 碘化N-甲基,乙基吗啉 硝酸吗啉 盐酸吗啡啉-D8 甲基吗啉-2-羧酸甲酯2,2,2-三氟乙酸盐 甲基N-[3-(乙酰基氨基)-4-[(2-氰基-4,6-二硝基苯基)偶氮]苯基]-N-乙基-&#x3B2-丙氨酸酸酯 甲基4-吗啉二硫代甲酸酯